retatrutide side effects women Lilly's shows 28% weight loss, but increased retatrutide side effects women GLP-1

Curious about what we know about GLP-1s so far

The key difference is selectivity: Melanotan II is a non-selective agonist activating MC1R, MC3R, MC4R, and MC5R, producing broader physiological effects including melanogenesis

This WORKS

Glucagon receptor agonism increases hepatic glucose output and is hypothesised to promote lipolysis and increase energy expenditure, though the magnitude of this effect in humans is uncertain and context-dependent

This pattern suggests Canadian approval for Retatrutide could occur around 2028-2029 if the US approval timeline holds at 2026-2027

This issue is particularly relevant in epithelial organs such as the kidney, where tubular cells are aligned along the nephron axis but are not necessarily in continuous plasma membrane contact